BLAINTRAVENOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDERPriority Review
Approved
Feb 2023
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
LAMZEDE (velmanase alfa-tycv) by Chiesi is alpha-mannosidosis is a lysosomal storage disease that results from reduced activity of the enzyme alpha-mannosidase, caused by gene variants in mannosidase alpha class 2b member 1. First approved in 2023.
Drug data last refreshed 40m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LAMZEDE (velmanase alfa-tycv) is an enzyme replacement therapy for alpha-mannosidosis, a rare lysosomal storage disease caused by deficiency of the enzyme alpha-mannosidase. The drug provides an exogenous source of alpha-mannosidase that is internalized via mannose-6-phosphate receptor binding and transported into lysosomes to degrade accumulated mannose-rich oligosaccharides. It is administered intravenously as a lyophilized powder for injection.
Peak
Early-stage peak lifecycle with minimal competitive pressure (30%) suggests growing commercial infrastructure and active field expansion opportunities.
Mechanism of Action
Alpha-mannosidosis is a lysosomal storage disease that results from reduced activity of the enzyme alpha-mannosidase, caused by gene variants in Mannosidase Alpha Class 2B Member 1. Alpha-mannosidase catalyzes the degradation of accumulated mannose-containing oligosaccharides. The deficiency of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3
Started Feb 2025
5 enrolled
Alpha-Mannosidosis
Career Relevance
Working on LAMZEDE offers a focused career in rare disease commercialization with deep patient engagement and specialist HCP relationships. The ultra-niche indication requires expertise in orphan drug access strategies, genetic testing partnerships, and regional reimbursement navigation.
Worked on LAMZEDE at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.